{'fraction_non_alphanumeric': 0.03510392609699769, 'fraction_numerical': 0.021709006928406466, 'mean_word_length': 5.333333333333333, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Abstract IA12: Preventing melanoma progression through a genomic approach


 The InterMEL Program Project has been designed to fill a gap in our knowledge about the biology and clinical course of Stage II and Stage III melanoma. This program, Integration of Clinical and Molecular Biomarkers for Melanoma Survival, is work from a consortium of 12 institutions, using primary melanomas, and differs from the TCGA, which was 80% metastatic melanoma. We are attempting to use genomics (next-gen sequencing, methylation analyses, miRNA, and expression analyses) to form an integrated signature for survival among those diagnosed with Stages II and III melanoma. Such a signature could assist clinicians in determining whether to treat the patient, prior to metastases, with newer therapies or to less aggressively follow those patients unlikely to die of their disease. To do this, we are evaluating 1,000 tumors—500 from those who died from melanoma within 5 years, and 500 from those who lived more than 5 years without progression. Expert pathologists review each lesion for eligibility and classification of clinical characteristics. These tumors have not been treated with immunotherapy or targeted therapies. Full clinical information is available for each tumor, including age, sex, race/ethnicity, anatomic site, histologic subtype, AJCC8 stage, sentinel lymph node status, Breslow thickness, ulceration, mitotic index, TILs, regression, satellites, tumor purity, date of progression (if progressed), vital status, follow-up time to death or last contact. To date, we have clinical and pathologic data on more than 500 of the 1,000 tumors and genomic data on more than 100 of these. We find better survival among those with higher mutation burden, poorer survival among those with a CIMP methylation phenotype, and a number of miRNAs associated with survival.
 Citation Format: Marianne Berwick, InterMEL. Preventing melanoma progression through a genomic approach [abstract]. In: Proceedings of the AACR Special Conference on Melanoma: From Biology to Target; 2019 Jan 15-18; Houston, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(19 Suppl):Abstract nr IA12.